Fecal transplant (FMT) and depression

Development of the therapy

Interest in FMT for mood disorders followed two parallel observations: animal studies in which transferring stool from depressed humans into germ-free rodents reproduced depression-like behaviour, and human studies showing that people with major depressive disorder (MDD) carry a measurably altered gut microbiome.¹The first open-label human FMT pilots in depression were published from 2020 onward and reported short-term improvements in HAM-D and HAM-A scores in patients with treatment- resistant disease.²

Therapeutic target

The proposed mechanism is the gut–brain axis: microbial metabolites (short-chain fatty acids, tryptophan derivatives, secondary bile acids), vagal afferent signalling, and modulation of systemic inflammation can all influence mood-regulating circuits. FMT is hypothesised to nudge these pathways by shifting the metabolite-producing community, rather than by acting on a single molecular target the way an SSRI does.³

What the trials show

• Pilot scale. Published trials are open-label, mostly single-arm, with 10–30 participants per study.
• Short-term mood improvements on standardised depression and anxiety scales at 4–8 weeks, in patients who had failed multiple antidepressants.
• Microbiome shifts toward donor-like communities correlate weakly with response in some studies.
• No randomised, sham-controlled, long-term trials have yet been published. Placebo response in psychiatric trials is large, so uncontrolled signals must be interpreted cautiously.

Possible side effects and risks

• Transient GI symptoms (bloating, cramping, altered bowel habit) in the first days
• Procedural risks of the chosen FMT route
• Theoretical risk of donor-derived shifts in mood, cognition, or weight — areas where long-term human data are sparse
• Risk of patients delaying or substituting evidence-based depression treatments while pursuing experimental FMT

FAQ: FMT in depression

Anyone struggling with depression should work with a psychiatrist or GP. Experimental microbiome therapies are not a substitute for evidence-based mental health care.

References

1. Kelly JR, et al. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res. 2016.
2. Doll JPK, et al. Fecal microbiota transplantation (FMT) as an adjunctive therapy for depression — case report. Front Psychiatry. 2022.
3. Cryan JF, et al. The Microbiota–Gut–Brain Axis. Physiol Rev. 2019.